Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development
Emily J. Lodge, … , Constantine A. Stratakis, Cynthia L. Andoniadou
Emily J. Lodge, … , Constantine A. Stratakis, Cynthia L. Andoniadou
Published October 27, 2020
Citation Information: JCI Insight. 2020;5(23):e134310. https://doi.org/10.1172/jci.insight.134310.
View: Text | PDF
Research Article Development Endocrinology

Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development

  • Text
  • PDF
Abstract

Pituitary developmental defects lead to partial or complete hormone deficiency and significant health problems. The majority of cases are sporadic and of unknown cause. We screened 28 patients with pituitary stalk interruption syndrome for mutations in the FAT/DCHS family of protocadherins that have high functional redundancy. We identified 7 variants, 4 of which are putatively damaging, in FAT2 and DCHS2 in 6 patients with pituitary developmental defects recruited through a cohort of patients with mostly ectopic posterior pituitary gland and/or pituitary stalk interruption. All patients had growth hormone deficiency, and 2 presented with multiple hormone deficiencies and small glands. FAT2 and DCHS2 were strongly expressed in the mesenchyme surrounding the normal developing human pituitary. We analyzed Dchs2–/– mouse mutants and identified anterior pituitary hypoplasia and partially penetrant infundibular defects. Overlapping infundibular abnormalities and distinct anterior pituitary morphogenesis defects were observed in Fat4–/– and Dchs1–/– mouse mutants, but all animal models displayed normal commitment to anterior pituitary cell types. Together our data implicate FAT/DCHS protocadherins in normal hypothalamic-pituitary development and identify FAT2 and DCHS2 as candidates underlying pituitary gland developmental defects such as ectopic pituitary gland and/or pituitary stalk interruption.

Authors

Emily J. Lodge, Paraskevi Xekouki, Tatiane S. Silva, Cristiane Kochi, Carlos A. Longui, Fabio R. Faucz, Alice Santambrogio, James L. Mills, Nathan Pankratz, John Lane, Dominika Sosnowska, Tina Hodgson, Amanda L. Patist, Philippa Francis-West, Françoise Helmbacher, Constantine A. Stratakis, Cynthia L. Andoniadou

×

Figure 3

DCHS2 is required for normal murine pituitary development.

Options: View larger image (or click on image) Download as PowerPoint
DCHS2 is required for normal murine pituitary development.
(A) Immunoflu...
(A) Immunofluorescence staining using antibodies against Ki-67 to detect cycling cells, on frontal sections of pituitaries from Dchs2–/– mutants and WT littermate controls at 18.5 dpc. Graph depicting quantification of cycling cells of the anterior pituitary of WT controls and Dchs2–/– mutants, showing reduced proliferation in mutants in the marginal zone (MZ) surrounding the cleft P = 0.0495, parenchyme (Par) P = 0.007, and total throughout the anterior lobe P = 0.0044, unpaired Student’s t test (n = 3 per genotype, multiple sections counted). Values of Ki-67–positive cells are expressed as a percentage of the total nuclei in the anterior lobe. Average values are indicated. *P < 0.05; **P < 0.01. (B) Immunofluorescence staining on Dchs2–/– pituitaries and littermate controls at 18.5 dpc (n = 3) using antibodies against lineage-committed progenitor markers PIT1 (thyrotrophs, somatotrophs, lactotrophs), SF1 (gonadotrophs), and TPIT (corticotrophs, melanotrophs) and hormones TSH, GH, and ACTH expressed in differentiated thyrotrophs, somatotrophs, and corticotrophs, respectively. Staining is comparable for all markers between genotypes. (C) Hematoxylin and eosin staining on frontal sections of Dchs2–/– mutants and controls at 18.5 dpc at axial levels as indicated in the cartoon (n = 6). Abnormal invaginations are seen in the median eminence (arrowheads) as well as lobulated protrusions (arrow). PL, posterior lobe; IL, intermediate lobe; AL, anterior lobe; Hyp, hypothalamus; M, mesenchyme; Sph, sphenoid bone. Scale bars: 200 μm (A and B), 250 μm (C).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts